S6 Ep7: Tagawa Breaks Down FGFR Testing and the Use of Erdafitinib in Bladder Cancer

OncLive® On Air - A podcast by OncLive® On Air

Podcast artwork

Dr. Tagawa discusses the incidence and identification of FGFR alterations in bladder cancer, the approval and use of erdafitinib in the second-line setting for patients with advanced bladder cancer, and research directions with the FGFR inhibitor in the field.